Researchers from Cardiff University have discovered a new class of highly potent and selective inhibitors targeting the LIM domain kinases (LIMKs), a family of enzymes that play a critical role in regulating actin filament turnover. This turnover is involved in the cytoskeletal remodeling, proliferation and migration.

Researchers at Zhengzhou University and two of its affiliated hospitals explored in a mouse model whether brozopine might mitigate ischemia-induced vascular dementia.

Palobiofarma SL has announced the successful completion of an industrial research project investigating dual antagonist compounds targeting adenosine A2A and histamine H3 receptors for the treatment of Parkinson’s disease.

Two independent studies have linked neuronal injury, inside or outside the brain, to cancer progression and offer new biomarkers and strategies for prevention. While cerebral cancer cells damage axons and drive tumor development, in other types of cancer affecting other organs, nerve disruption caused by tumor proximity triggers inflammation and a suppressive environment that may also be associated with immunotherapy resistance.

Leal Therapeutics Inc. has raised $30 million in series A financing to advance its neuro-metabolic pipeline of therapeutics that aim to correct metabolic imbalances in the brain in patients with neuropsychiatric or neurodegenerative disorders.

Aging is marked by a gradual decline in body function, partly driven by the buildup of senescent cells. These cells stop dividing but release a mix of inflammatory and tissue-remodeling factors, known as the senescence-associated secretory phenotype (SASP).

Individuals who develop antibodies against the GluN1 subunit of NMDA receptors can develop NMDA receptor encephalitis (NMDARE), which can lead to psychosis, cognitive deficits and movement disorders. Current treatments are not effective in all patients, and many patients relapse after treatment.